<div id="readability-page-1"><p>Natixis bought a new position in  Nuvation Bio Inc. (NYSE:NUVB - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 905,500 shares of the company's stock, valued at approximately $1,766,000. Natixis owned about 0.27% of Nuvation Bio as of its most recent filing with the Securities and Exchange Commission (SEC).</p><p>Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Pale Fire Capital SE lifted its stake in shares of  Nuvation Bio by 109.5% in the 2nd quarter. Pale Fire Capital SE now owns 95,642 shares of the company's stock worth $187,000 after purchasing an additional 50,000 shares during the period.  Cerity Partners LLC bought a new position in  Nuvation Bio in the second quarter worth approximately $97,000.  Morton Community Bank purchased a new position in shares of  Nuvation Bio during the 2nd quarter worth $59,000.  Cresset Asset Management LLC grew its position in shares of  Nuvation Bio by 3.5% during the 2nd quarter. Cresset Asset Management LLC now owns 143,690 shares of the company's stock valued at $280,000 after acquiring an additional 4,874 shares during the period.  Finally, Tema Etfs LLC purchased a new stake in shares of  Nuvation Bio in the 2nd quarter worth $272,000. Hedge funds and other institutional investors own  61.67% of the company's stock. </p><h2>Insider Buying and Selling</h2><p>In other Nuvation Bio news, insider Dongfang Liu sold 150,000 shares of the firm's stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $7.82, for a total transaction of $1,173,000.00. Following the completion of the transaction, the insider owned 18,000 shares in the company, valued at $140,760. This trade represents a 89.29% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Gary Hattersley sold 100,000 shares of the stock in a transaction that occurred on Monday, October 27th. The shares were sold at an average price of $5.02, for a total value of $502,000.00. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 320,000 shares of company stock valued at $2,050,800. 29.93% of the stock is owned by corporate insiders. </p><h2>Wall Street Analyst Weigh In</h2><p>Several analysts have issued reports on NUVB shares. HC Wainwright boosted their price target on Nuvation Bio from $10.00 to $18.00 and gave the company a &#34;buy&#34; rating in a report on Thursday. JMP Securities  set a $10.00 target price on shares of Nuvation Bio in a research note on Thursday, November 20th. Weiss Ratings  reiterated a &#34;sell (d-)&#34; rating on shares of Nuvation Bio in a research note on Wednesday, October 8th. Citizens Jmp raised their price target on Nuvation Bio from $8.00 to $10.00 and gave the company a &#34;market outperform&#34; rating in a report on Thursday, November 20th. Finally, Wall Street Zen upgraded Nuvation Bio from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Sunday, August 17th. One analyst  has rated the stock with a Strong Buy rating, nine have given a Buy rating and one  has assigned  a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $10.56.</p><p><b>Read Our Latest Report on Nuvation Bio</b></p><h2>Nuvation Bio Stock Performance</h2><p>Shares of NYSE NUVB opened at $8.27 on Friday. The company has a market cap of $2.84 billion, a P/E ratio of -12.92 and a beta of 1.58. Nuvation Bio Inc. has a 52-week low of $1.54 and a 52-week high of $8.95. The company has a debt-to-equity ratio of 0.14, a quick ratio of 8.39 and a current ratio of 8.48. The firm's fifty day moving average is $5.59 and its two-hundred day moving average is $3.62. </p><p>Nuvation Bio (NYSE:NUVB - Get Free Report) last released its quarterly earnings data on Monday, November 3rd. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.01. Nuvation Bio had a negative net margin of 813.07% and a negative return on equity of 54.99%. The business had revenue of $13.12 million during the quarter, compared to the consensus estimate of $7.48 million.  As a group, analysts anticipate that  Nuvation Bio Inc. will post -0.36 EPS for the current fiscal year. </p><h2>Nuvation Bio Profile</h2> (Free Report)<p>Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Nuvation Bio</li><li>Health Care Stocks Explained: Why You Might Want to Invest</li><li>3 Recently Downgraded Stocks to Avoid in 2026</li><li>What is a Death Cross in Stocks?</li><li>The Chip Boom Is Back: 3 Stocks Positioned for Huge Gains</li><li>The 3 Best Fintech Stocks to Buy Now</li><li>Oracle Stock Hit Hard: Why Its AI Pipeline Could Drive a 2026 Rally</li></ul><p><strong>Want to see what other hedge funds are holding NUVB?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nuvation Bio Inc. (NYSE:NUVB - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5VVkI?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5VVkI"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Nuvation Bio Right Now?</h2><p>Before you consider Nuvation Bio, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nuvation Bio wasn't on the list.</p><p>While Nuvation Bio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

NUVB

<p>Natixis acquired 905,500 shares of Nuvation Bio Inc., valued at $1,766,000, during Q2. Insider Dongfang Liu sold 150,000 shares, while Gary Hattersley sold 100,000 shares. Analysts have mixed ratings, with HC Wainwright raising the price target to $18.00 and Weiss Ratings issuing a sell rating. Nuvation Bio's stock opened at $8.27, with a market cap of $2.84 billion.</p>

Natixis Buys Shares of 905,500 Nuvation Bio Inc. $NUVB